Aditxt (ADTX) Stock Is Falling After Hours: What Is Going On?

Aditxt Inc. (NASDAQ:ADTX) shares fell 33.94% in after-hours trading on Tuesday following an SEC Form 4 filing disclosing that major shareholder HRT Financial LP purchased 4.25 million shares at $0.016 per share on June 12. Despite the insider purchase, the stock continued to face selling pressure, closing the regular session down 15.50% at $0.011 before declining further to $0.0072 after hours. The stock has lost nearly 100% of its value over the past 12 months and hit a 52-week low of $0.0090.

06/17/2026, 1:31 AM • Benzinga

What's Going On With Aditxt Stock Wednesday?

Aditxt announced a definitive business combination agreement to separate its subsidiary Ignite Proteomics into an independent public company valued at approximately $150 million. The transaction aims to unlock value and provide Ignite with greater access to growth capital for its precision oncology platform. However, Aditxt shares fell 28.55% in premarket trading Wednesday, trading at $0.02, as the stock remains in a steep downtrend with extremely oversold technical indicators and minimal chart support.

06/10/2026, 7:56 AM • Benzinga

Stock Market Today: S&P 500, Dow Futures Gain As Jobs Data Weighs On Outlook—Lennar, Micron Technology, Children's Place In Focus (UPDATED)

U.S. stock futures rose on Wednesday after a mixed market close, with uncertainty surrounding November's jobs report and potential Federal Reserve interest rate decisions. Key companies reported earnings with varied results.

12/17/2025, 8:26 AM • Benzinga

Stock Market Today: S&P 500, Dow Futures Gain As Jobs Data Weighs On Outlook—Lennar, Micron Technology, Children's Place In Focus

U.S. stock futures rose on Wednesday after a mixed Tuesday close, with market uncertainty surrounding November's jobs report and potential Federal Reserve interest rate decisions. Key companies reported earnings with varied results.

12/17/2025, 5:39 AM • Benzinga

Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update

Women's health company Evofem Biosciences reported increased net sales of $5.0 million in Q3 2025, a 10% increase from the previous year. The company achieved $1.0 million in operating income, reduced operating expenses by 42%, and advanced strategies to lower manufacturing costs for its products PHEXX and SOLOSEC.

11/13/2025, 4:05 PM • Benzinga

Evofem Announces Voting Results from Special Meeting of Stockholders

Evofem Biosciences shareholders rejected a proposed merger with Aditxt, leading the company to terminate the merger agreement and pivot towards regaining a national stock listing and securing growth capital.

10/20/2025, 4:19 PM • Benzinga

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Evofem Biosciences launched a provocative "Say Vagina" campaign in August 2025, generating over 2.5 million social media views and increasing website traffic by 130%, aimed at normalizing medical terminology and women's health discussions.

09/11/2025, 9:18 AM • Benzinga

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Evofem Biosciences plans to merge with Aditxt, with a stockholder meeting scheduled for September 26, 2025. The company believes it has sufficient voting support to approve the merger, which would position Evofem as a subsidiary of Aditxt focused on women's healthcare innovations.

09/09/2025, 9:28 AM • Benzinga

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Evofem Biosciences announced a new U.S. patent for SOLOSEC, its single-dose oral treatment for bacterial vaginosis and trichomoniasis, which extends patent protection until December 2041.

08/19/2025, 9:39 AM • Benzinga

Evofem Revenue Jumps 16 Percent in Q2

Evofem Biosciences reported Q2 2025 financial results with 16% revenue growth to $4.8 million, driven by SOLOSEC acquisition and PHEXXI price adjustment. Despite operational improvements, the company experienced a net loss of $1.8 million and faces liquidity challenges ahead of a pending merger with Aditxt.

08/14/2025, 9:07 AM • The Motley Fool

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Women's health innovator Evofem Biosciences reported increased net sales of $4.8 million in Q2 2025, improved operational losses, and advanced global market strategies for its contraceptive and antibiotic products while preparing for a merger with Aditxt.

08/14/2025, 8:46 AM • Benzinga

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Evofem Biosciences CEO Saundra Pelletier received the Trailblazing Female Founders Award at the 2025 STIMULATE Conference in Nashville, recognizing her leadership in women's sexual health and reproductive innovation.

08/05/2025, 8:46 AM • Benzinga

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Phexxi, a non-hormonal birth control brand by Evofem Biosciences, gained significant social media attention through a viral TikTok about 'microfeminism', attracting coverage from BuzzFeed, MSN, and Scary Mommy while sparking conversations about women's health autonomy.

07/15/2025, 9:12 AM • Benzinga

Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

Appili Therapeutics announced its fiscal year 2025 results, highlighting the re-launch of LIKMEZ metronidazole oral suspension, progress on its tularemia vaccine candidate ATI-1701, and a topical antiparasitic product ATI-1801. The company submitted five U.S. government funding proposals totaling up to $125 million and reported a net loss of $2.6 million.

06/25/2025, 6:04 PM • GlobeNewswire